The Power of Truth® has been released for sale and assignment to a conservative pro-American news outlet, cable network, or other media outlet that wants to define and brand its operation as the bearer of the truth, and set itself above the competition.

In every news story the audience hears of censorship, speech, and the truth. The Power of Truth® has significant value to define an outlet, and expand its audience. A growing media outlet may decide to rebrand their operation The Power of Truth®. An established outlet may choose to make it the slogan distinguishing their operation from the competition. You want people to think of your outlet when they hear it, and think of the slogan when they see your company name. It is the thing which answers the consumer's questions: Why should I choose you? Why should I listen to you? Think:

  • What’s in your wallet -- Capital One
  • The most trusted name in news – CNN
  • Fair and balanced - Fox News
  • Where’s the beef -- Wendy’s
  • You’re in good hands -- Allstate
  • The ultimate driving machine -- BMW

The Power of Truth® is registered at the federal trademark level in all applicable trademark classes, and the sale and assignment includes the applicable domain names. The buyer will have both the trademark and the domains so that it will control its business landscape without downrange interference.

Contact: Truth@ThePowerOfTruth.com

Friday, September 20, 2024
Friday, September 20, 2024

Microbial communities are thought to contain keystone species, which can disproportionately affect the stability of the communities, even if only present in low abundances. Identifying these keystone species can be challenging, especially in the human gut, since it is not feasible to isolate them through systematic elimination. Researchers have designed a new data-driven keystone species identification (DKI) framework that uses machine learning to resolve this difficulty. 
Read more …Study proposes new framework to identify keystone microbial species

Researchers have discovered a 'genomic tug of war' in animal studies that could influence how well certain patients -- or certain cancers -- respond to decitabine, a drug used to treat myelodysplastic syndromes that is plagued by drug resistance issues. For the first time, researchers show that decitabine causes coding and non-coding regions of DNA to engage in a tug of war for a gene activator, called H2A.Z. Typically, deticabine draws this gene activator away from coding DNA, causing gene expression to grind to a halt and cells to die. However, many types of cancer have very high levels of H2A.Z, which may help them overcome this decitabine-induced tug of war, allowing the cancer to grow.
Read more …Genomic tug of war could boost cancer therapy

More Articles …

  1. Hunger hormones impact decision-making brain area to drive behavior
  2. A small molecule blocks aversive memory formation, providing a potential treatment target for depression
  3. Breakthrough in bladder cancer research
  4. FDA's latest warnings about eye drop contamination put consumers on edge − a team of infectious disease experts explain the risks
  5. Casgevy: UK approves gene-editing drug for blood disorders
  6. Casgevy: UK approves gene-editing drug for sickle cell
Page 726 of 926